Husereau Don, Dempster William, Blanchard Adrienne, Chambers Johanne
Institute of Health Economics, Edmonton, AB, Canada; Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada.
3Sixty Public Affairs, Inc., Ottawa, ON, Canada.
Value Health. 2014 Dec;17(8):888-94. doi: 10.1016/j.jval.2014.08.2673. Epub 2014 Nov 4.
Canada has a unique system of public drug coverage and reimbursement characterized by a centralized review agency that makes funding recommendations along with decentralized authority for delivering health care across 10 provinces and three territories. There has been a significant increase in price negotiation for new pharmaceuticals in the past 10 years, first by individual provinces and now through a collective price negotiation process called the "Pan-Canadian Pharmaceutical Alliance." As of February 2014, the Pan-Canadian Pharmaceutical Alliance has already completed 32 negotiations despite still being in a formative stage; it is anticipated that a formal process will be developed in the coming year. In this article, we describe the evolution of price negotiation in Canada and identify several opportunities for improvement of the current process, including the incorporation of economic considerations into price negotiation.
加拿大拥有独特的公共药品覆盖和报销体系，其特点是有一个中央审查机构负责提出资金建议，同时在10个省和3个地区拥有分散的医疗保健提供权力。在过去10年里，新药品价格谈判显著增加，先是个别省份进行谈判，现在则通过一个名为“泛加拿大药品联盟”的集体价格谈判过程进行。截至2014年2月，尽管仍处于形成阶段，泛加拿大药品联盟已经完成了32次谈判；预计明年将制定一个正式程序。在本文中，我们描述了加拿大价格谈判的演变，并确定了当前程序改进的几个机会，包括将经济因素纳入价格谈判。
